Albert Einstein College of Medicine
The Bronx, New York, 10461, United States
NCT Number: NCT07526948
This is a research study about the effects of vaginal estradiol compared to moisturizer on vaginal symptoms of menopause and the microbiome in women with HIV. This research study aims to understand how vaginal products affect the aging of the female genital tract in women living with HIV who are menopausal or perimenopausal and have vaginal or urinary symptoms. There is a comparison group of women who are living without HIV. Participants with HIV and vaginal or urinary menopausal symptoms (e.g., dryness, irritation, soreness, itching, pain with sex, dysuria, urgency, or frequent urinary tract infections) will be asked to apply vaginal estradiol or a vaginal moisturizer (Replens). Participants who have vaginal or urinary menopausal symptoms and do not have HIV will receive vaginal estradiol.
Trial opening soon.
Get Notified40 year–70 year
Female
Interventional
Phase 4
The Bronx, New York, 10461, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Using a pre-loaded single-use plastic applicator, participants will insert one 10 microgram estradiol tablet intravaginally daily for 2 weeks and then one tablet twice weekly for the remainder of the study for a total of 16 weeks.
Other names: Vagifem
Using a pre-loaded single-use plastic applicator, participants will insert one vaginal moisturizer applicator intravaginally twice weekly for the duration of the study for a total of 12 weeks.
Other names: Replens
Time frame: From Baseline to 16 weeks
Changes in the vaginal microbiome as defined by the change in alpha diversity from baseline to 16 weeks will be assessed. It is hypothesized that this may be a biomarker for improvement in vaginal health. Lower alpha diversity would indicate a favorable change in the microbiome.
Time frame: From Baseline to 16 weeks
Using a survey administered at each visit, participants will rate the severity of five vaginal (dryness, itching, irritation, soreness, and dyspareunia) and three urinary (frequency, urgency, recurrent UTIs) symptoms based on a four-point scale (0=none, 1=mild, 2=moderate, 3=severe). A composite GSM symptom index will be calculated as the mean severity of the corresponding symptoms at each visit. A higher score indicates increased severity of symptoms.
It is anticipated that both vaginal estradiol and the vaginal moisturizer will lead to improvement in the symptoms of the genitourinary syndrome of menopause.
Contact information is provided by the study sponsor or research team.
Kerry J Murphy, MD
CONTACT
Marla J Keller, MD
CONTACT
Albert Einstein College of Medicine
Other
Vaginal Estradiol Versus Moisturizer to Improve Postmenopausal Vaginal Aging Symptoms, Dysbiosis and Markers of Latency Reversal in Menopausal Women Living With HIV
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07606326
Adnexal Diseases, Bone Diseases
View Trial DetailsNCT07427459
Menopausal Complaints, Perimenopause
Decorah, Iowa, United States
View Trial DetailsNCT07667699
Atrophy, Bone Mineral Density
View Trial DetailsNCT07538895
Menopausal Complaints
Banī Suwayf, Beni Suweif Governorate, Egypt
View Trial Details